Screener
Ginkgo Bioworks DNA Q2 2026 earnings
Reported August 5, 2026 · After market close
Revenue$20.2MMiss by $3.9M
EPS-$0.75Beat by $0.15
Revenue estimate$24.1M
EPS estimate-$0.90
“Autonomous labs are increasingly becoming necessary national infrastructure for American science. The White House and the National Science Foundation are now investing billions to move experimentation off the bench and into AI-enabled labs that scientists can run from anywhere, and Ginkgo is proud to be helping build that future—both with Nebula, already the world's largest autonomous lab, and by powering several of the new NSF cloud lab nodes with our automation. We're using that same infrastructure to bring high-value R&D back onshore to the U.S., and to help lead the transition from the manual lab bench to autonomous research infrastructure that runs 24/7 and plugs directly into the AI models transforming drug discovery.”
Next report
Nov 5, 2026 (in 2 months)Revenue estimate$21.6M
EPS estimate-$0.58
Valuation & ratios
Segments
By segment
Versus estimates
Revenue
Diluted EPS
FAQ
- When did Ginkgo Bioworks report Q2 2026 earnings?
- Ginkgo Bioworks (DNA) reported Q2 2026 earnings on August 5, 2026 after market close.
- What were Ginkgo Bioworks's Q2 2026 revenue and EPS?
- Ginkgo Bioworks reported revenue of $20.2M and eps of $-0.75 for Q2 2026.
- Did Ginkgo Bioworks beat estimates in Q2 2026?
- Revenue missed the consensus estimate of $24.1M by $3.9M. EPS beat the consensus estimate of $-0.90 by $0.15.
- How did Ginkgo Bioworks's Q2 2026 results compare year-over-year?
- Compared to the same quarter a year prior, revenue declined 59.4% from $49.6M a year earlier and eps grew 31.8% from $-1.10.
- Where can I find Ginkgo Bioworks's Q2 2026 SEC filings?
- You can read the 8-K earnings release (0001628280-26-053319) and the 10-Q periodic report (0001628280-26-054298) directly on SEC EDGAR. The filing index links above go to sec.gov.
